Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Niagen Bioscience (NAGE) Total Current Liabilities (2016 - 2025)

Historic Total Current Liabilities for Niagen Bioscience (NAGE) over the last 15 years, with Q3 2025 value amounting to $22.7 million.

  • Niagen Bioscience's Total Current Liabilities rose 2832.36% to $22.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $22.7 million, marking a year-over-year increase of 2832.36%. This contributed to the annual value of $17.9 million for FY2024, which is 1296.67% down from last year.
  • As of Q3 2025, Niagen Bioscience's Total Current Liabilities stood at $22.7 million, which was up 2832.36% from $22.3 million recorded in Q2 2025.
  • Over the past 5 years, Niagen Bioscience's Total Current Liabilities peaked at $22.7 million during Q3 2025, and registered a low of $16.2 million during Q2 2021.
  • Over the past 5 years, Niagen Bioscience's median Total Current Liabilities value was $18.2 million (recorded in 2023), while the average stood at $18.8 million.
  • As far as peak fluctuations go, Niagen Bioscience's Total Current Liabilities plummeted by 1296.67% in 2024, and later surged by 2832.36% in 2025.
  • Niagen Bioscience's Total Current Liabilities (Quarter) stood at $17.6 million in 2021, then rose by 1.45% to $17.9 million in 2022, then grew by 15.41% to $20.6 million in 2023, then fell by 12.97% to $17.9 million in 2024, then grew by 26.54% to $22.7 million in 2025.
  • Its last three reported values are $22.7 million in Q3 2025, $22.3 million for Q2 2025, and $20.8 million during Q1 2025.